



# *Pharmaceuticals in the Environment*

**29 November 2017  
16:30-18:30  
Room JDE51  
Committee of the Regions**

Co-chaired by:

**Michel Dantin MEP**

Chair of the “*Water & Agriculture*” Working Group of the EP Intergroup on  
“*Climate Change, Biodiversity, and Sustainable Development*”

**Peter Liese MEP**

ENVI Committee Coordinator for EPP

EN-FR

The Priority Substances Directive adopted by the European Parliament and the Council of the EU in 2013, requires the European Commission **to develop a strategic approach to pollution of water by pharmaceutical substances** by September 2015. After some delay, the European Commission will shortly launch the public consultation on the strategic approach, gathering the views from citizens, public authorities and stakeholders.

In this meeting of the ‘Agriculture and Water Management’ working group we will learn more about the ongoing internal work of the European Commission and we will bring all relevant stakeholders together, from industry and civil society, to discuss the developments at EU and national level, taking into account the two complementary dimensions: the environmental protection perspective as well as the protection of public health.

The debate aims to provide food for thought in the context of the upcoming reviews of the Water Framework Directive and the Priority Substances Directive starting in 2018.



### DRAFT AGENDA

- 16:30-16:40** Welcome and introduction by **Michel Dantin MEP**
- 16:40-16:50** Keynote speech by **Bettina Doeser**, Head of Unit Clean Water, European Commission, DG Environment
- 16:50-17:00** **Dr. Babette Winter**, Committee of Regions, State Secretary for Europe and Culture in the Thuringia State Chancellery
- 17:00-17:10** **Jan Peter van der Hoek**, Professor of Drinking Water Engineering, TU Delft (for EUREAU)
- 17:10-17:20** **Bengt Mattson**, Chair of the Pharmaceuticals in the Environment Task Force, European Federation of Pharmaceutical Industries and Associations (EFPIA)
- 17:20-17:30** **Adela Maghear**, Pharmaceuticals Policy Officer, Healthcare without Harm Europe
- 17:30-18:20** **Discussion with the audience**
- 18:20-18:30** Closing remarks by **Peter Liese MEP**